Biomark Diagnostics Stock Today
| BMKDF Stock | USD 0.15 0.01 6.25% |
Performance0 of 100
| Odds Of DistressLess than 10
|
BioMark Diagnostics is trading at 0.15 as of the 11th of December 2024. This is a 6.25 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.15. BioMark Diagnostics has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 19th of August 2023 and ending today, the 11th of December 2024. Click here to learn more.
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.. The company has 83.29 M outstanding shares. More on BioMark Diagnostics
Moving together with BioMark Pink Sheet
Moving against BioMark Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BioMark Pink Sheet Highlights
| Business Concentration | Diagnostics & Research, Healthcare (View all Sectors) |
BioMark Diagnostics [BMKDF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioMark Diagnostics's market, we take the total number of its shares issued and multiply it by BioMark Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioMark Diagnostics classifies itself under Healthcare sector and is part of Diagnostics & Research industry. The entity has 83.29 M outstanding shares.
BioMark Diagnostics has accumulated about 364.96 K in cash with (1.2 M) of positive cash flow from operations.
Check BioMark Diagnostics Probability Of Bankruptcy
Ownership AllocationBioMark Diagnostics holds a total of 83.29 Million outstanding shares. BioMark Diagnostics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BioMark Ownership Details
BioMark Diagnostics Risk Profiles
| Mean Deviation | 2.23 | |||
| Standard Deviation | 5.19 | |||
| Variance | 26.95 | |||
| Risk Adjusted Performance | (0.05) |
BioMark Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BioMark Diagnostics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
BioMark Diagnostics Corporate Executives
Elected by the shareholders, the BioMark Diagnostics' board of directors comprises two types of representatives: BioMark Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioMark. The board's role is to monitor BioMark Diagnostics' management team and ensure that shareholders' interests are well served. BioMark Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioMark Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neal Kaplan | CFO of US | Profile |
Other Information on Investing in BioMark Pink Sheet
BioMark Diagnostics financial ratios help investors to determine whether BioMark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioMark with respect to the benefits of owning BioMark Diagnostics security.